ScreenerHero

VERUVeru Inc.

NAS · US · Healthcare · Biotechnology · verupharma.com
2.640USD0.00%Mkt Cap: 45.01M $P/E: —

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and inter…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap45.01M $
Enterprise Value20.94M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.73M $
Revenue/Share—
Last Price2.640 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92536C1036
Valuation
P/E (Trailing)—
P/E (Forward)-2.62
PEG3.60
EV/EBITDA-0.76
EV/Revenue—
P/S—
P/B2.10
EPS (TTM)-0.59
EPS (Forward)-0.98
52W Range
2.05011% of range7.330
52W High7.330 USD
52W Low2.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-123.97%
ROA-76.17%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.04M $
CapEx (TTM)1.08K $
FCF Margin—
FCF Yield-32.09%
Net Debt-23.05M $
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity0.17
Current Ratio4.42
Quick Ratio4.18
Book Value/Sh1.231 USD
Cash/Share1.510 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield3.71%
Payout Ratio0.00%
Ex-Div DateApr 28, 2014
Pay DateMay 7, 2014
Splits
Last Split1:10
Split DateAug 11, 2025
Analyst Consensus
Rating—
Target (Mean)24.50 USD
Upside (mean)+828.0%
Target Range24.00 USD – 25.00 USD
$24.00+828.0% to mean$25.00
# Analysts2
Ownership
Shares Out.17.05M
Float15.48M
Insiders9.22%
Institutions19.70%
Short Interest
Short Ratio5.0d
Short % Float8.96%
Short % Out.8.13%
Shares Short1.39M
Short (prev mo.)683.40K
Technical
SMA 502.664 (-0.9%)
SMA 2002.484 (+6.3%)
Beta-1.20
S&P 52W Chg18.16%
Avg Vol (30d)269.10K
Avg Vol (10d)337.94K
Technical Indicators
RSI (14)54.9
MACD0.0389
MACD Signal-0.0029
MACD Hist.+0.0419
BB Upper2.891 USD
BB Middle2.449 USD
BB Lower2.007 USD
BB Width36.14%
ATR (14)0.1582 USD
Vol Ratio (20d)0.62x